Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

LifeStance Health Group Q3 2026 Results: Net Income $22.4M, Up 1978.5% YoY

LifeStance Health Group reported a significant improvement in financial performance for the third quarter of 2026, with total revenue increasing to $455.9 million compared to $363.8 million in the prior year. The company achieved a net income of $22.4 million for the quarter, a substantial increase from $1.1 million in the same period of 2025, driven by strong growth in income from operations.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue455.9363.8
Profit before tax27.44.6
Net income22.41.1

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Net income, year on year+1978.5%
Revenue, year on year+25.3%
Operating margin7.3%
Source

10-Q filed with the SEC, NASDAQ: LFST. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

LifeStance Health Group, Inc.: key numbers

Share price
$14.17Close, Nov 17
Market cap
$5.39B
Shares outstanding
380.19MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Services-Health ServicesSIC 8000

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from LifeStance Health Group, Inc.

All →
4:28 PM ET Form 4
Insider Selling

LifeStance Health Group Insider TPG Gp a LLC Sells $485M of Stock

TPG Gp a LLC sold 37,233,110 shares of LifeStance Health Group, Inc. at $13.02 a share, worth $485M in total on Nov 12, 2026. Shares held after the trade: 42,458,592 (-46.7%).

Value
$485M
Shares
37,233,110
Price
$13.02
Holding change
-46.7%
Trade date
Nov 12, 2026
9:05 PM ET Form 4
Insider Selling

LifeStance Health Group Insider Ryan Pardo Sells $40.9M of Stock

Ryan Pardo sold 2,804,505 shares of LifeStance Health Group, Inc. at $14.58 a share, worth $40.9M in total on Nov 10, 2026. Shares held after the trade: 334,935 (-86.9%).

Value
$40.9M
Shares
2,804,505
Average price
$14.58
Holding change
-86.9%
Trade date
Nov 10, 2026
5:00 PM ET Form 4
Insider Selling

LifeStance Health Group Director Kenneth A. Burdick Sells $2.05M of Stock

Kenneth A. Burdick, Director, sold 141,589 shares of LifeStance Health Group, Inc. at $14.41 to $14.60 a share (average $14.51) in 2 transactions, worth $2.05M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 2,904,221 (-2.5%).

Value
$2.05M
Shares
141,589
Average price
$14.51
Role
Director
Holding change
-2.5%
Trade date
Nov 9, 2026 to Nov 10, 2026
5:00 PM ET Form 4
Insider Selling

LifeStance Health Group COO Lisa K. Miller Sells $215K of Stock

Lisa K. Miller, COO, sold 14,663 shares of LifeStance Health Group, Inc. at $14.68 a share, worth $215K in total on Nov 11, 2026. Shares held after the trade: 251,904 (-5.5%).

Value
$215K
Shares
14,663
Price
$14.68
Role
COO
Holding change
-5.5%
Trade date
Nov 11, 2026
4:33 PM ET 8-K
M&A Deal

LifeStance Health Group M&A Deal with Selling Stockholders

LifeStance Health Group, Inc. entered into an underwriting agreement for a secondary offering of 45,000,000 shares of common stock sold by existing stockholders. The company did not receive any proceeds from the sale, but it repurchased 2,000,000 of these shares from the underwriters as part of the transaction.

Counterparty
Selling Stockholders
6:03 AM ET 8-K
Financial Results

LifeStance Health Group Financial Results

LifeStance Health Group reported Q3 2026 revenue of $455.9 million, a 25% increase year-over-year, driven by higher visit volumes and clinician growth. The company significantly improved profitability, reporting net income of $22.4 million compared to $1.1 million in the prior year, and raised its full-year 2026 revenue and Adjusted EBITDA guidance.

Term
Q3 2026

“The team delivered a tremendous quarter, with execution across the business driving results that once again exceeded our expectations. The strong momentum gives us the confidence to further raise our full-year 2026 outlook across all financial metrics, while our positive patient outcomes, most recently across TMS and Spravato, reflect our commitment to clinical excellence.”

Dave Bourdon, CEO of LifeStance

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.